225 related articles for article (PubMed ID: 17206118)
1. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Hatfield A; Owen S; Pilot PR
Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
[No Abstract] [Full Text] [Related]
2. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Rosti G; Martinelli G; Baccarani M
Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121
[No Abstract] [Full Text] [Related]
3. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Atallah E; Kantarjian H; Cortes J
Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119
[No Abstract] [Full Text] [Related]
4. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E
Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117
[No Abstract] [Full Text] [Related]
5. Cardiotoxicity of imatinib: At the heart of the problem.
Tiribelli M; Medeot M
Leuk Res; 2011 Jan; 35(1):36-7. PubMed ID: 20970188
[No Abstract] [Full Text] [Related]
6. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
7. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate.
Baker DE
Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
[TBL] [Abstract][Full Text] [Related]
9. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
10. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
11. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Mcpherson T; Sherman V; Turner R
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
[No Abstract] [Full Text] [Related]
12. [Management of chronic myeloid leukemia by imatinib].
Kizaki M
Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
[No Abstract] [Full Text] [Related]
13. Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
Hong FS; Mitchell CA; Zantomio D
Pathology; 2010 Jan; 42(1):84-5. PubMed ID: 20025487
[No Abstract] [Full Text] [Related]
14. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
[No Abstract] [Full Text] [Related]
15. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Kerkelä R; Grazette L; Yacobi R; Iliescu C; Patten R; Beahm C; Walters B; Shevtsov S; Pesant S; Clubb FJ; Rosenzweig A; Salomon RN; Van Etten RA; Alroy J; Durand JB; Force T
Nat Med; 2006 Aug; 12(8):908-16. PubMed ID: 16862153
[TBL] [Abstract][Full Text] [Related]
16. Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib.
Meng HT; Li Y; Jin J; Qian WB; Yang CM
Ann Hematol; 2007 Mar; 86(3):231-2. PubMed ID: 17123082
[No Abstract] [Full Text] [Related]
17. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
18. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
Shimizu K; Kuroda H; Kida M; Watanabe H; Shirao S; Akiyama T; Fujimi A; Tanaka I; Sato T; Matsunaga T; Niitsu Y
Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
20. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
[No Abstract] [Full Text] [Related]
[Next] [New Search]